Find your path to Phillip
808 people in our graph share verified history with Phillip — schools, employers, funds. One of them is your warm intro.
About
Phillip Samayoa is a venture partner with over 15 years of experience as a biotech investor, executive, and company builder. He most recently was chief scientific officer and chief strategy officer at Generation Bio, where he built business development, portfolio strategy, and discovery research functions and raised over $750M across financings and partnerships. He was previously a principal on the Atlas investment team, co-founded Generation Bio and Dyne Therapeutics, and earlier held roles at Merck's MRL Ventures Fund and Flagship Pioneering; he holds a Ph.D. in systems biology from UC San Diego and dual B.S. degrees from MIT.
Invests in
Biotech
Experience
- Atlas VentureVenture Partnercurrent2026 — presentCambridge, Massachusetts
- Generation BioCo-Founder and Chief Scientific Officer2025
- Generation BioChief Strategy Officer2022 — 2025Cambridge, Massachusetts, United States
- Generation BioSenior Vice President, Head of Corporate Development2021 — 2022Cambridge, Massachusetts
- Generation BioVice President, Strategy and Portolio Development2018 — 2021
- Generation BioSenior Director, Strategy and Portfolio Development2017 — 2018
- Dyne TherapeuticsCo-Founder2017 — 2018
- Atlas VenturePrincipal2016 — 2018Cambridge, Massachusetts
- Translate BioBoard Observer2015 — 2016Cambridge, MA
- MerckPrincipal, MRL Ventures2016Cambridge, MA
- MerckAssociate, MRL Ventures2015 — 2016Cambridge, MA
- Flagship PioneeringAssociate2012 — 2015Cambridge, MA
- Flagship PioneeringVentureLabs Entrepreneurial Fellow2012Cambridge, MA
- Codiak BiosciencesCo-Founder2014 — 2015Cambridge, MA
- IndigoFounding Team2014Cambridge, MA
- AxcellaProduct Strategy and Intellectual Property2012 — 2014Cambridge, MA
- Bayer Technology ServicesComputational Systems Biology2009
- Decision ResourcesConsulting2008
- Infinity PharmaceuticalsCancer Biochemistry2007
Skills & more
+8 more
Genetic EngineeringMolecular CloningCell CultureMicrofluidicsPhotolithographyMicrofabricationVenture CapitalEntrepreneurshipFrom Phillip's professional profile.
Investments
Investor
Per the firm's website.
Colleagues at Atlas Venture
Frequently asked questions
- Who is Phillip Samayoa?
- Phillip Samayoa is a venture partner with over 15 years of experience as a biotech investor, executive, and company builder. He most recently was chief scientific officer and chief strategy officer at Generation Bio, where he built business development, portfolio strategy, and discovery research functions and raised over $750M across financings and partnerships. He was previously a principal on the Atlas investment team, co-founded Generation Bio and Dyne Therapeutics, and earlier held roles at Merck's MRL Ventures Fund and Flagship Pioneering; he holds a Ph.D. in systems biology from UC San Diego and dual B.S. degrees from MIT.
- Where does Phillip Samayoa work?
- Phillip Samayoa is Venture Partner at Atlas Venture.
- What does Phillip Samayoa invest in?
- Phillip Samayoa invests in Biotech.
- What companies has Phillip Samayoa invested in?
- Investments tracked here include Dyne Therapeutics, Generation Bio.
- Where did Phillip Samayoa go to school?
- Phillip Samayoa studied at Massachusetts Institute of Technology (Dual S.B., Biological Engineering); UC San Diego (PhD, Bioinformatics and Systems Biology).
Founder mafias
Massachusetts Institute of Technology mafia1,432
Also came through, then founded or led a company.
UC San Diego mafia296
Also came through, then founded or led a company.
Atlas Venture mafia33
Also came through, then founded or led a company.
Flagship Pioneering mafia29
Also came through, then founded or led a company.
Dyne Therapeutics mafia5
Also came through, then founded or led a company.
Same school
Also attended Massachusetts Institute of Technology2,000
+ 1,994 more
Also attended UC San Diego580
+ 574 more
Shared employers
Also worked at Generation Bio3
Also worked at Dyne Therapeutics6
Also worked at Translate Bio2
Also worked at Merck262
+ 256 more























































